Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer's disease and multiple sclerosis

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 4, 2015, Pages 471-487

  Srinivasan, Mythily ^a   Lahiri, Debomoy K ^b  

^a INDIANA UNIVERSITY SCHOOL OF DENTISTRY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; amyloid; disease modifying agents; drug target; multiple sclerosis; natural compounds; neurodegeneration; neuroinflammation; NF B; polyphenols; promoter; terpenoids; therapeutic target mechanism

Indexed keywords

CORTICOSTEROID; CURCUMIN; EPIGALLOCATECHIN GALLATE; FINGOLIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOTIDE; PEPTIDE; POLYPHENOL; POLYPHENOLIC CURCUMINOID DERIVATIVE; RESVERATROL; TERPENOID; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ARTICLE; CENTRAL NERVOUS SYSTEM; CORTICOSTEROID THERAPY; DISEASE COURSE; HUMAN; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; UPREGULATION;

ALZHEIMER DISEASE; ANIMALS; DRUG DESIGN; HUMANS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; NF-KAPPA B; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84924917150     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.989834     Document Type: Article

References (100)

1. Camandola S, Mattson MP. NF-kappa B as a therapeutic target in neurodegenerative diseases. Expert Opin Ther Targets 2007;11(2):123-32
2. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008;29(8):357-65
3. Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration. Cell 2010;140(6):918-34
4. Gupta SC, Sundaram C, Reuter S, et al. Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 2010;1799(10-12):775-87
5. Kaltschmidt C, Kaltschmidt B, Neumann H, et al. Constitutive NF-kappa B activity in neurons. Mol Cell Biol 1994;14(6):3981-92
6. Sarnico I, Lanzillotta A, Benarese M, et al. NF-kappaB dimers in the regulation of neuronal survival. Int Rev Neurobiol 2009;85:351-62
7. Mattson MP, Meffert MK. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ 2006;13(5):852-60
8. Terai K, Matsuo A, McGeer PL. Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res 1996;735(1):159-68
9. Kaltschmidt B, Ndiaye D, Korte M, et al. NF-kappaB regulates spatial memory formation and synaptic plasticity through protein kinase A/CREB signaling. Mol Cell Biol 2006;26(8):2936-46
10. Goffi F, Boroni F, Benarese M, et al. The inhibitor of I kappa B alpha phosphorylation BAY 11-7082 prevents NMDA neurotoxicity in mouse hippocampal slices. Neurosci Lett 2005;377(3):147-51
11. Listwak SJ, Rathore P, Herkenham M. Minimal NF-kappaB activity in neurons. Neuroscience 2013;250:282-99
12. Sierra A, Abiega O, Shahraz A, et al. Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis. Front Cell Neurosci 2013;7:6
13. Pizzi M, Goffi F, Boroni F, et al. Opposing roles for NF-kappa B/Rel factors p65 and c-Rel in the modulation of neuron survival elicited by glutamate and interleukin-1beta. J Biol Chem 2002;277(23):20717-23
14. Pizzi M, Sarnico I, Boroni F, et al. Inhibition of IkappaBalpha phosphorylation prevents glutamate-induced NF-kappaB activation and neuronal cell death. Acta Neurochir Suppl 2005;93:59-63
15. Qin ZH, Tao LY, Chen X. Dual roles of NF-kappaB in cell survival and implications of NF-kappaB inhibitors in neuroprotective therapy. Acta Pharmacol Sin 2007;28(12):1859-72
16. Sambamurti K, Kinsey R, Maloney B, et al. Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J 2004;18(9):1034-6
17. Buggia-Prevot V, Sevalle J, Rossner S, et al. NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42. J Biol Chem 2008;283(15):10037-47
18. Chami L, Buggia-Prevot V, Duplan E, et al. Nuclear factor-kappaB regulates betaAPP and beta- and gamma-secretases differently at physiological and supraphysiological Abeta concentrations. J Biol Chem 2012;287(29):24573-84
19. Maloney B, Ge YW, Petersen RC, et al. Functional characterization of three single-nucleotide polymorphisms present in the human APOE promoter sequence: differential effects in neuronal cells and on DNA-protein interactions. Am J Med Genet B Neuropsychiatr Genet 2010;153B(1):185-201
20. Du Y, Chen X, Wei X, et al. NF-(kappa) B mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells. Brain Res Mol Brain Res 2005;136(1-2):177-88
21. Bamberger ME, Harris ME, McDonald DR, et al. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci 2003;23(7):2665-74
22. Schaeffer V, Meyer L, Patte-Mensah C, et al. Dose-dependent and sequence-sensitive effects of amyloid-beta peptide on neurosteroidogenesis in human neuroblastoma cells. Neurochem Int 2008;52(6):948-55
23. Valerio A, Boroni F, Benarese M, et al. NF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 production. Eur J Neurosci 2006;23(7):1711-20
24. Mattson MP, Goodman Y, Luo H, et al. Activation of NF-kappa B protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J Neurosci Res 1997;49(6):681-97
25. Pizzi M, Sarnico I, Boroni F, et al. NF-kappaB factor c-Rel mediates neuroprotection elicited by mGlu5 receptor agonists against amyloid beta-peptide toxicity. Cell Death Differ 2005;12(7):761-72
26. Boissiere F, Hunot S, Faucheux B, et al. Nuclear translocation of NF-kappaB in cholinergic neurons of patients with Alzheimer's disease. Neuroreport 1997;8(13):2849-52
27. Emmanouil M, Taoufik E, Tseveleki V, et al. A role for neuronal NF-kappaB in suppressing neuroinflammation and promoting neuroprotection in the CNS. Adv Exp Med Biol 2011;691:575-81
28. Ahmed T, Gilani AH. A comparative study of curcuminoids to measure their effect on inflammatory and apoptotic gene expression in an Abeta plus ibotenic acid-infused rat model of Alzheimer's disease. Brain Res 2011;1400:1-18
29. Bales KR, Du Y, Dodel RC, et al. The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. Brain Res Mol Brain Res 1998;57(1):63-72
30. Bordji K, Becerril-Ortega J, Nicole O, et al. Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-ss production. J Neurosci 2010;30(47):15927-42
31. Tsay HJ, Huang YC, Huang FL, et al. Amyloid beta peptide-mediated neurotoxicity is attenuated by the proliferating microglia more potently than by the quiescent phenotype. J Biomed Sci 2013;20(1):78
32. Hu J, Akama KT, Krafft GA, et al. Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res 1998;785(2):195-206
33. Zhao Y, Bhattacharjee S, Jones BM, et al. Regulation of neurotropic signaling by the inducible, NF-kB-sensitive miRNA-125b in Alzheimer's disease (AD) and in primary human neuronalglial (HNG) cells. Mol Neurobiol 2014;50(1):97-106
34. Pogue AI, Cui JG, Li YY, et al. Micro RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation. Neurosci Lett 2010;476(1):18-22
35. Pahan K, Schmid M. Activation of nuclear factor-kB in the spinal cord of experimental allergic encephalomyelitis. Neurosci Lett 2000;287(1):17-20
36. Miterski B, Bohringer S, Klein W, et al. Inhibitors in the NFkappaB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. Genes Immun 2002;3(4):211-19
37. Gveric D, Kaltschmidt C, Cuzner ML, et al. Transcription factor NF-kappaB and inhibitor I kappaBalpha are localized in macrophages in active multiple sclerosis lesions. J Neuropathol Exp Neurol 1998;57(2):168-78
38. Bonetti B, Stegagno C, Cannella B, et al. Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. Am J Pathol 1999;155(5):1433-8
39. Mc Guire C, Prinz M, Beyaert R, et al. Nuclear factor kappa B (NF-kappaB) in multiple sclerosis pathology. Trends Mol Med 2013;19(10):604-13
40. van Loo G, De Lorenzi R, Schmidt H, et al. Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat Immunol 2006;7(9):954-61
41. Hilliard B, Samoilova EB, Liu TS, et al. Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice:roles of NF-kappa B in the activation and differentiation of autoreactive T cells. J Immunol 1999;163(5):2937-43
42. Becher B, Segal BM. T(H)17 cytokines in autoimmune neuro-inflammation. Curr Opin Immunol 2011;23(6):707-12
43. Satoh J, Misawa T, Tabunoki H, et al. Molecular network analysis of T-cell transcriptome suggests aberrant regulation of gene expression by NF-kappaB as a biomarker for relapse of multiple sclerosis. Dis Markers 2008;25(1):27-35
44. Ridolfi E, Fenoglio C, Cantoni C, et al. Expression and Genetic Analysis of MicroRNAs Involved in Multiple Sclerosis. Int J Mol Sci 2013;14(3):4375-84
45. Huang TC, Lu KT, Wo YY, et al. Resveratrol protects rats from Abeta-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS One 2011;6(12):e29102
46. Imler TJ Jr, Petro TM. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression. Int Immunopharmacol 2009;9(1):134-43
47. Alisky JM. Intrathecal corticosteroids might slow Alzheimer's disease progression. Neuropsychiatr Dis Treat 2008;4(5):831-3
48. Lleo A, Galea E, Sastre M. Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell Mol Life Sci 2007;64(11):1403-18
49. Bergamaschi R, Versino M, Raiola E, et al. High-dose methylprednisolone infusions in relapsing and in chronic progressive multiple sclerosis patients. One year follow-up. Acta Neurol (Napoli) 1993;15(1):33-43
50. Clarner T, Parabucki A, Beyer C, et al. Corticosteroids impair remyelination in the corpus callosum of cuprizone-treated mice. J Neuroendocrinol 2011;23(7):601-11
51. Green KN, Billings LM, Roozendaal B, et al. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci 2006;26(35):9047-56
52. Ebrahimi A, Schluesener H. Natural polyphenols against neurodegenerative disorders: potentials and pitfalls. Ageing Res Rev 2012;11(2):329-45
53. Kauppinen A, Suuronen T, Ojala J, et al. Antagonistic crosstalk between NF-kappaB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal 2013;25(10):1939-48
54. Chen J, Zhou Y, Mueller-Steiner S, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005;280(48):40364-74
55. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002;20:55-72
56. Jang JH, Surh YJ. Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med 2003;34(8):1100-10
57. Solberg NO, Chamberlin R, Vigil JR, et al. Optical and SPION-enhanced MR imaging shows that trans-stilbene inhibitors of NF-kappaB concomitantly lower Alzheimer's disease plaque formation and microglial activation in AbetaPP/PS-1 transgenic mouse brain. J Alzheimers Dis 2014;40(1):191-212
58. Kim DW, Kim YM, Kang SD, et al. Effects of resveratrol and trans-3,5,4′-trimethoxystilbene on glutamate-induced cytotoxicity, heme oxygenase-1, and sirtuin 1 in HT22 neuronal cells. Biomol Ther (Seoul) 2012;20(3):306-12
59. Fonseca-Kelly Z, Nassrallah M, Uribe J, et al. Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Front Neurol 2012;3:84
60. Shindler KS, Ventura E, Dutt M, et al. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol 2010;30(4):328-39
61. Sato F, Martinez NE, Shahid M, et al. Resveratrol exacerbates both autoimmune and viral models of multiple sclerosis. Am J Pathol 2013;183(5):1390-6
62. Wang J, Du XX, Jiang H, et al. Curcumin attenuates 6-hydroxydopamine-induced cytotoxicity by anti-oxidation and nuclear factor-kappa B modulation in MES23.5 cells. Biochem Pharmacol 2009;78(2):178-83
63. Wang P, Su C, Li R, et al. Mechanisms and effects of curcumin on spatial learning and memory improvement in APPswe/PS1dE9 mice. J Neurosci Res 2014;92(2):218-31
64. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280(7):5892-901
65. Natarajan C, Bright JJ. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 2002;168(12):6506-13
66. Xie L, Li XK, Funeshima-Fuji N, et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol 2009;9(5):575-81
67. Zhang L, Wu C, Zhao S, et al. Demethoxycurcumin, a natural derivative of curcumin attenuates LPS-induced proinflammatory responses through downregulation of intracellular ROS-related MAPK/NF-kappaB signaling pathways in N9 microglia induced by lipopolysaccharide. Int Immunopharmacol 2010;10(3):331-8
68. Cui JG, Li YY, Zhao Y, et al. Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease. J Biol Chem 2010;285(50):38951-60
69. Cheng KK, Yeung CF, Ho SW, et al. Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer's disease Tg2576 mice. AAPS J 2013;15(2):324-36
70. Ray B, Lahiri DK. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol 2009;9(4):434-44
71. Lee SY, Lee JW, Lee H, et al. Inhibitory effect of green tea extract on beta-amyloid-induced PC12 cell death by inhibition of the activation of NF-kappaB and ERK/p38 MAP kinase pathway through antioxidant mechanisms. Brain Res Mol Brain Res 2005;140(1-2):45-54
72. Kim SJ, Jeong HJ, Lee KM, et al. Epigallocatechin-3-gallate suppresses NF-kappaB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells. J Nutr Biochem 2007;18(9):587-96
73. Lee JW, Lee YK, Ban JO, et al. Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice. J Nutr 2009;139(10):1987-93
74. Herges K, Millward JM, Hentschel N, et al. Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation. PLoS One 2011;6(10):e25456
75. de las Heras B, Hortelano S. Molecular basis of the anti-inflammatory effects of terpenoids. Inflamm Allergy Drug Targets 2009;8(1):28-39
76. Tran TA, McCoy MK, Sporn MB, et al. The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. J Neuroinflammation 2008;5:14
77. Martin R, Carvalho-Tavares J, Hernandez M, et al. Beneficial actions of oleanolic acid in an experimental model of multiple sclerosis: a potential therapeutic role. Biochem Pharmacol 2010;79(2):198-208
78. Zhao H, Wang SL, Qian L, et al. Diammonium glycyrrhizinate attenuates Abeta(1-42) -induced neuroinflammation and regulates MAPK and NF-kappaB pathways in vitro and in vivo. CNS Neurosci Ther 2013;19(2):117-24
79. Qi Y, Zou LB, Wang LH, et al. Xanthoceraside inhibits pro-inflammatory cytokine expression in Abeta25-35/IFN-gamma-stimulated microglia through the TLR2 receptor, MyD88, nuclear factor-kappaB, and mitogen-activated protein kinase signaling pathways. J Pharmacol Sci 2013;122(4):305-17
80. Yin QQ, Liu CX, Wu YL, et al. Preventive and therapeutic effects of adenanthin on experimental autoimmune encephalomyelitis by inhibiting NF-kappaB signaling. J Immunol 2013;191(5):2115-25
81. Jiao J, Xue B, Zhang L, et al. Triptolide inhibits amyloid-beta1-42-induced TNF-alpha and IL-1beta production in cultured rat microglia. J Neuroimmunol 2008;205(1-2):32-6
82. Pan XD, Chen XC, Zhu YG, et al. Tripchlorolide protects neuronal cells from microglia-mediated beta-amyloid neurotoxicity through inhibiting NF-kappaB and JNK signaling. Glia 2009;57(11):1227-38
83. Kizelsztein P, Komarnytsky S, Raskin I. Oral administration of triptolide ameliorates the clinical signs of experimental autoimmune encephalomyelitis (EAE) by induction of HSP70 and stabilization of NF-kappaB/IkappaBalpha transcriptional complex. J Neuroimmunol 2009;217(1-2):28-37
84. Kim MO, Si Q, Zhou JN, et al. Interferon-beta activates multiple signaling cascades in primary human microglia. J Neurochem 2002;81(6):1361-71
85. Grimaldi LM, Zappala G, Iemolo F, et al. A pilot study on the use of interferon beta-1a in early Alzheimer's disease subjects. J Neuroinflammation 2014;11:30
86. Sochocka M, Zaczynska E, Tabol A, et al. The influence of donepezil and EGb 761 on the innate immunity of human leukocytes: effect on the NF-kappaB system. Int Immunopharmacol 2010;10(12):1505-13
87. Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 2013;328(1-2):9-18
88. Wu C, Leong SY, Moore CS, et al. Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation. J Neuroinflammation 2013;10:41
89. Bruck W, Pfortner R, Pham T, et al. Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol 2012;124(3):411-24
90. Delgado M, Varela N, Gonzalez-Rey E. Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia 2008;56(10):1091-103
91. Tan YV, Waschek JA. Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis. ASN Neuro 2011;3(4):196-212
92. Cuny GD. Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions. Curr Pharm Des 2009;15(34):3919-39
93. Munoz L, Ralay Ranaivo H, Roy SM, et al. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation 2007;4:21
94. Huang X, Chen Y, Zhang H, et al. Salubrinal attenuates beta-amyloid-induced neuronal death and microglial activation by inhibition of the NF-kappaB pathway. Neurobiol Aging 2012;33(5):1007.e1009-17
95. Fisher L, Samuelsson M, Jiang Y, et al. Targeting cytokine expression in glial cells by cellular delivery of an NF-kappaB decoy. J Mol Neurosci 2007;31(3):209-19
96. Dasgupta S, Jana M, Zhou Y, et al. Antineuroinflammatory effect of NF-kappaB essential modifier-binding domain peptides in the adoptive transfer model of experimental allergic encephalomyelitis. J Immunol 2004;173(2):1344-54
97. Takada Y, Singh S, Aggarwal BB. Identification of a p65 peptide that selectively inhibits NF-kappa B activation induced by various inflammatory stimuli and its role in down-regulation of NF-kappaB-mediated gene expression and up-regulation of apoptosis. J Biol Chem 2004;279(15):15096-104
98. Srinivasan M, Janardhanam S. Novel p65 binding glucocorticoid-induced leucine zipper peptide suppresses experimental autoimmune encephalomyelitis. J Biol Chem 2011;286(52):44799-810
99. Srinivasan M, Blackburn C, Lahiri D. Functional characterization of a competitive peptide antagonist of p65 in human macrophage like cells suggests a therapeutic potential for chronic inflammation. Drug Des Dev Ther 2014; In press
100. Catala-Lopez F, Genova-Maleras R, Vieta E, et al. The increasing burden of mental and neurological disorders. Eur Neuropsychopharmacol 2013;23(11):1337-9